Clinical Takeaway
In a controlled crossover trial of healthy adults, CBD at both low (30 mg) and high (700 mg) single doses showed no direct effect on cortical excitability compared to placebo. This suggests that CBD’s anti-seizure benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend more on its pharmacokinetic interaction with clobazam than on a direct brain-quieting effect. Clinicians should keep this distinction in mind when evaluating CBD as a standalone versus adjunctive therapy.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may derive primarily from pharmacokinetic interactions with concurrent antiepileptic drugs rather than direct effects on neuronal excitability, fundamentally reshaping how clinicians should interpret and optimize CBD-based therapies. Understanding that CBD lacks direct cortical suppression has important implications for dosing strategies, drug interaction monitoring, and patient counseling regarding expected mechanisms of action. These findings suggest that CBD’s seizure-reducing benefits in approved indications depend critically on coadministered medications, necessitating careful polypharmacy assessment in clinical practice.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This rigorously designed crossover trial provides important mechanistic clarity by demonstrating that CBD lacks direct effects on cortical excitability in healthy volunteers, suggesting its seizure-reduction benefit in approved indications may depend substantially on pharmacokinetic interactions with concurrent medications like clobazam rather than intrinsic anti-epileptic properties. The study’s strength lies in its controlled design and homogeneous population, though we must note that findings in healthy subjects may not fully translate to the neurophysiologic state of patients with severe epilepsy syndromes, and acute dosing in this paradigm differs from chronic therapeutic use. This distinction matters clinically: when prescribing CBD as adjunctive therapy, we should remain attentive to potential drug-drug interactions and avoid assumptions about CBD’s standalone anti-seizure efficacy in patients not concurrently using interacting ASMs. The practical takeaway is that CBD’s documented benefit in Dravet and Lennox-Gastaut syndromes likely reflects a pharmaco